Alchemedicine, Inc. / Japan
Alchemedicine is pre-clinical stage biotech focusing on innovative small molecule drug discovery. In our medicinal chemistry-driven R&D strategy, we are agnostic to disease area and many discovery programs are actively ongoing. We focus on early drug discovery stage, from unique drug design to lead optimization. We identified some clinical candidate compounds, ALK5 inhibitor, CK1 inhibitor, ETA antagonist and ALDH2 activator. We are seeking for partner to establish collaboration or licensing of our compound.
We need collaboration or drug discovery partners.
ALK5 inhibitor (for Cancers, IPF, FECD)
CK1 inhibitor (for Cancers, ALS, Circadian rhythm disorder)
ETA antagonist (for IgA nephropathy, FSGS, Diabetic nephropathy, etc)
ALDH2 activator (for Fanconi anemia, etc)